Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

KVUE US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Kenvue Inc.(KVUE US)

$19.33-0.100.51%Ext:$19.60+0.271.41%(After Hours · 23:00:12 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Kenvue Inc. — Company Profile

Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.

Sector
Consumer Discretionary
Industry
Specialty Retail
Exchange
UN
CEO
Kirk L. Perry
Headquarters
Summit, NJ, US
IPO Date
May 4, 2023
Employees
21,890
Website
www.kenvue.com

Key Metrics

Price
$17.20
Market Cap
$33.02B
Revenue (TTM)
$3.91B
Net Income (TTM)
$474.00M
EPS (TTM)
0.25
P/E (TTM)
20.36
P/B (TTM)
3.11
Dividend Yield
4.83%
ROE (TTM)
4.47%
ROA (TTM)
1.77%
Operating Margin
21.87%
Beta
0.10

Dividends

Last Dividend
$0.21
Last Yield
0.05%

Summary

Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.

Website
www.kenvue.com
Location
Summit, NJ, US
Phone908 874 1200
Employees21,890
CEOKirk L. Perry
Sector
Consumer Discretionary
Industry
Specialty Retail
IPO DateMay 4, 2023

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(490)

Expand
  • 8-KEntry into a Material Definitive Agreement13 Oct
  • 4Statement of changes in beneficial ownership6 Oct
  • 4Statement of changes in beneficial ownership6 Oct
  • 4Statement of changes in beneficial ownership6 Oct
  • 4Statement of changes in beneficial ownership6 Oct
  • 4Statement of changes in beneficial ownership6 Oct
  • 4Statement of changes in beneficial ownership5 Oct
  • 4Smith Jeffrey C29 Sep
  • 4Statement of changes in beneficial ownership29 Sep
  • 4Statement of changes in beneficial ownership29 Sep
  • SC 13G/AKenvue Inc.6 Aug
  • 10-QQ2ended 28 Jun 20266 Aug
  • 8-KResults of Operations and Financial Condition6 Aug
  • 4Statement of changes in beneficial ownership4 Aug
  • 4Smith Jeffrey C1 Jul
  • 4Statement of changes in beneficial ownership1 Jul
  • 4Statement of changes in beneficial ownership12 Jun
  • 144Howlett Heather10 Jun
  • SDSD28 May
  • 4Smith Jeffrey C26 May

News

  • Kimberly-Clark Corporation Announces Extension of the Expiration Date for Exchange Offers for Kenvue Notes27 Oct
  • 4 Big-Name Dividend Stocks Paying Yields Most Blue Chips Can't Match27 Oct
  • Kimberly-Clark: The Dividend Survives Kenvue, But Expect Token Raises23 Oct
  • 3 Beauty Stocks to Explore as Consumer Preferences Reshape the Market22 Oct
  • Kenvue to Announce Third Quarter 2026 Results on October 30, 202621 Oct
  • October's 5 Dividend Growth Stocks With Yields Up To 7.99%19 Oct
  • First Citizens Bank & Trust Co. Purchases New Position in Kenvue Inc. $KVUE17 Oct
  • Kimberly-Clark, Kenvue Win Conditional EU Approval for $40 Billion Tie-Up13 Oct
  • Kimberly-Clark Announces Successful Consent Solicitations for Kenvue Notes and Amendment to Terms of Exchange Offers13 Oct
  • Market Concentration Is Spooking Wall Street—I'm Buying Kenvue8 Oct
  • NWL or KVUE: Which Is the Better Value Stock Right Now?6 Oct
  • 4 Dividend Aristocrats Still Raising Their Payouts No Matter What Their Stock Price Did4 Oct
  • Kimberly-Clark Announces Planned Executive Transitions and Updates to Post-Closing Leadership Team1 Oct
  • 5 ‘Bulletproof’ Dividend Kings Boomers Should Buy Now Before the Market Shifts30 Sep
  • Kimberly-Clark Pays Out Almost Everything It Earns. Can the Dividend Survive the Kenvue Deal?29 Sep
  • Kimberly-Clark Corporation Announces Commencement of Exchange Offers and Consent Solicitations for Kenvue Notes28 Sep
  • Burning a Hole in My Pocket27 Sep
  • Kimberly-Clark offers remedies in bid for EU approval of Kenvue deal23 Sep
  • 5 Beaten-Down Dividend Kings Ready to Roar Back in 2027 (One Yields Over 5%)22 Sep
  • The Moneymaxxing Crowd Will Love 5 High-Yield Dividend Stocks Under $2018 Sep

Mentions in Filings

  • … “Kimberly-Clark”), announced that it has extended the expiration date of its previously announced offers to exchange (each, an “Exchange Offer” and, collectively, the “Exchange Offers”) any and all outstanding notes (the “<strong>Kenvue</strong> Notes”) issued by Kenvue Inc., a Delaware corporation (“Kenvue”), for up to $7.0 billion aggregate principal amount of new notes issued by Kimberly-Clark. Kimberly-Clark extended such expiration date from 5:00 p.m., New …
    KIMBERLY CLARK CORPKenvue Inc.·8-K - Other Events·Q4 26·27 Oct
  • … tial offering memorandum and consent solicitation statement dated September 28, 2026 (as amended from time to time, including by this press release, the “Offering Memorandum”) is hereby amended to incorporate by reference <strong>Kenvue</strong>’s unaudited consolidated financial statements and related notes for the three and nine months ended September 27, 2026 and September 28, 2025 that will be included in Kenvue's Quarterly Report on Form 10-Q to be filed wit …
    KIMBERLY CLARK CORPKenvue Inc.·EX-99.1 - 8-K - Other Events·Q4 26·27 Oct
  • … the Offering will be completed on or about October 29, 2026, subject to customary closing conditions. The Offering is being conducted in connection with the previously announced proposed acquisition (“Acquisition”) of <strong>Kenvue Inc.</strong> (“Kenvue”), which is expected to be consummated in the fourth quarter of 2026, subject to the satisfaction of certain customary closing conditions. The Notes are being offered only to persons who are either reasonably b …
    KIMBERLY CLARK CORPKenvue Inc.·8-K - Other Events·Q4 26·20 Oct
  • The Offering is being conducted in connection with the previously announced proposed acquisition (“Acquisition”) of <strong>Kenvue Inc.</strong> (“Kenvue”), which is expected to be consummated in the fourth quarter of 2026, subject to the satisfaction of certain customary closing conditions. Kimberly-Clark intends to use the net proceeds from the Offering, together with cash on hand and/or borrowings under its commercial paper program, to fund the cash considerat …
    KIMBERLY CLARK CORPKenvue Inc.·EX-99.1 - 8-K - Other Events·Q4 26·20 Oct
  • early tenders as of 5:00 p.m., New York City time, on October 9, 2026 (the “Early Participation Date”), the requisite number of consents have been received to adopt the Amendments with respect to all outstanding series of <strong>Kenvue</strong> Notes. Kenvue has executed a supplemental indenture with respect to the Kenvue Indenture implementing the Amendments. The Amendments will become operative only upon settlement of the Exchange Offers. The settlement date f …
    KIMBERLY CLARK CORPKenvue Inc.·8-K - Other Events·Q4 26·13 Oct
  • As of 5:00 p.m., New York City time, on October 9, 2026 (the “Early Participation Date”), the principal amounts of <strong>Kenvue</strong> Notes set forth in the table below were validly tendered and not validly withdrawn (and consents thereby validly given and not validly revoked). For each $1,000 principal amount of Kenvue Notes validly tendered and not validly withdrawn at or prior to the Early Participation Date and accepted by Kimberly-Clark, Eligible Holder …
    KIMBERLY CLARK CORPKenvue Inc.·EX-99.1 - 8-K - Other Events·Q4 26·13 Oct

Key Stats

Trading

Px/Chg 1D$17.20 / -0.12%
Avg Volume22.45M
Beta0.10
Mkt Cap33.02B
FD Mkt Cap36.43B

Float

Shrs Out/Float1.92B / 1.92B
Short Float0.03%
Days to Cover2.35
Stock Repurchased$0.00

Current Valuation

EV40.61B
EV/EBITDA12.81
EV/Sales2.66
P/B3.11
P/S2.16
FCF Yield1.06%
ROE4.47%
ROA1.77%
Current Ratio0.98

Dividend

Cash$0.21
Yield4.83%
Yield (TTM)4.83%

Estimates

P/E20.36
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMay '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings59.5022.7242.97102.6569.67
Price / Sales5.682.452.868.968.45
Price / Book Value3.553.374.583.153.11
Price / Free Cash Flow46.7614.0133.1545.5394.35
ENTERPRISE VALUE METRICS
Enterprise Value44,676.644,854.851,904.741,336.940,610.1
Enterprise Value / Sales6.902.903.3610.9410.39
Enterprise Value / EBITDA35.5314.1321.0362.3544.63
Enterprise Value / EBIT44.3517.6028.1278.7452.95

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue11.6%15,054.014,950.015,444.015,455.015,124.0
Gross Income1.1%8,419.08,285.08,643.08,959.08,792.0
EBITDA-5.3%3,656.03,281.03,175.02,468.02,935.0
EBIT-5%2,925.02,637.02,548.01,846.02,378.0
Net Income-8.3%2,078.02,064.01,664.01,030.01,470.0
EPS (Diluted)-8.8%1.101.080.870.540.76
BALANCE SHEET
Cash & ST Inv9.5%740.01,231.01,382.01,070.01,062.0
Total Assets-77.2%27,929.027,316.027,851.025,601.027,076.0
Total Liabilities21.3%7,530.07,346.016,640.015,933.016,311.0
Total Shareholder Equity-14.8%20,399.019,970.011,211.09,668.010,765.0
CASH FLOW
Net Operating Cash Flow60.1%334.02,525.03,168.01,769.02,197.0
Cap Ex12.6%-295.0-375.0-469.0-434.0-475.0
Free Cash Flow157.8%39.02,150.02,699.01,335.01,722.0

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)19.57
Basic Shares1,920.01
Market Cap37,574.6
Diluted Shares1,922.00
Fully Diluted Shares Outstanding1,922.00
Fully Diluted Market Cap37,613.5
+Consolidated Debt8,661.0
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-1,075.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value45,160.6

Segment data

Revenue

by Products and services

  • Self Care42%
  • Essential Health31%
  • Skin Health And Beauty27%

Revenue

by Geography

  • North America48%
  • Emea25%
  • Asia Pacific18%
  • Latin America9%

Related companies

Colgate Palmolive Co

CL US

Bandai Namco Holdings Inc.

NCBDY US

Haleon plc

HLN US

Estee Lauder Companies Inc

EL US

ANTA Sports Products Ltd / ADR

ANPDY US

Pop Mart International Group Limited/ADR

9992 HK

Clorox Co /DE/

CLX US

Life Time Group Holdings, Inc.

LTH US

Games Workshop Group Plc/adr

GMWKF US

Chemed Corp

CHE US

e.l.f. Beauty, Inc.

ELF US

Acushnet Holdings Corp.

GOLF US